Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M

Natera, Inc.

2022-Q2 EPS reported -$2.95 revenue$392,333,000

Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).
Tests processed ~499,900, up 33% YoY; net loss $145.2M ($1.50/share) vs $116.0M ($1.32).
2022 revenue guidance raised to $805M-$825M; gross margin ~46%-48%.
Cash & investments $638.7M, down from $914.5M at Dec 31, 2021; net cash consumption expected $370M-$400M.
Selected for UnitedHealthcare Preferred Lab Network; Medicare coverage for Signatera in muscle invasive bladder cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.